Potential and limitations of PKA/ PKG inhibitors for platelet studies
- 30 November 2021
- journal article
- research article
- Published by Taylor & Francis in Platelets
- Vol. 33 (6) , 859-868
Abstract
Cyclic nucleotides (cAMP and cGMP) and corresponding protein kinases, protein kinase A (PKA) and protein kinase G (PKG), are the main intracellular mediators of endothelium-derived platelet inhibitors. Pharmacological PKA/PKG inhibitors are often used to discriminate between these two kinase activities and to analyze their underlying mechanisms. Previously we showed that all widely used PKG inhibitors (KT5823, DT3, RP isomers) either did not inhibit PKG or inhibited and even activated platelets independently from PKG. In this study, we examined several PKA inhibitors as well as inhibitors of adenylate and guanylate cyclases to reveal their effects on platelets and establish whether they are mediated by PKA/PKG. The commonly used PKA inhibitor H89 inhibited both PKA and PKG but PKA-independently inhibited thrombin-induced platelet activation. In our experiments, KT5720 did not inhibit PKA and had no effect on platelet activation. PKI inhibited PKA activity in platelets but also strongly PKA-independently activated platelets. Inhibition of adenylate and guanylate cyclases may be an alternative approach to analyze PKA/PKG function. Based on our previous and presented data, we conclude that all results where the mentioned PKA inhibitors were used for the analysis of PKA activity in intact platelets should be considered with caution.Keywords
Funding Information
- NR were supported (AAA-A18-118012290142-9)
- The Russian Foundation for Basic Research (No. 19-315-90102)
This publication has 32 references indexed in Scilit:
- Lack of effect of ODQ does not exclude cGMP signalling via NO‐sensitive guanylyl cyclaseBritish Journal of Pharmacology, 2013
- Phosphorylation of CalDAG‐GEFI by protein kinase A prevents Rap1b activationJournal of Thrombosis and Haemostasis, 2013
- The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathwaysBlood, 2012
- The oligopeptide DT‐2 is a specific PKG I inhibitor only in vitro, not in living cellsBritish Journal of Pharmacology, 2012
- Thrombin and Collagen Induce a Feedback Inhibitory Signaling Pathway in Platelets Involving Dissociation of the Catalytic Subunit of Protein Kinase A from an NFκB-IκB ComplexJournal of Biological Chemistry, 2010
- Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular systemJournal of Clinical Investigation, 2006
- cGMP-dependent Protein Kinase Type II Regulates Basal Level of Aldosterone Production by Zona Glomerulosa Cells without Increasing Expression of the Steroidogenic Acute Regulatory Protein GeneJournal of Biological Chemistry, 2003
- The specificities of protein kinase inhibitors: an updateBiochemical Journal, 2003
- Cyclic Nucleotides Modulate Store-mediated Calcium Entry through the Activation of Protein-tyrosine Phosphatases and Altered Actin Polymerization in Human PlateletsJournal of Biological Chemistry, 2001
- Analysis and Regulation of Vasodilator-stimulated Phosphoprotein Serine 239 Phosphorylation in Vitro and in Intact Cells Using a Phosphospecific Monoclonal AntibodyJournal of Biological Chemistry, 1998